While weekly MTX treatment, at parenteral doses up to 15 mg/m2, is an effective and safe therapy in JIA [10,11], pediatric patients not responding to MTX may now have other treatment options with the anti-TNF-α therapies etanercept and adalimumab [12,13]. Here, TNF is linked to juvenile idiopathic arthritis.